

**MTN 011 - A Phase 1 Impact of Coitus on PK PD of Tenofvir 1% Gel Following Pericoital or Daily Gel Dosing
Data as of July 30, 2015**

Accrual Summary by Site (Couples)

Site	Activation Date	First Enrollment Date	Last Enrollment Date¹	Duration of Accrual² (weeks)	Enrollment Target	Total Enrolled	Average Enrolled per Week	Percent Enrolled
Cleveland, OH	01NOV2012	21DEC2012	28FEB2014	62.1	24	13	0.2	54.2%
Pittsburgh, PA	19NOV2012	25JAN2013	25FEB2014	56.7	16	18	0.3	112.5%
All Sites	01NOV2012	21DEC2012	28FEB2014	62.1	40	31	0.5	77.5%

¹Duration of accrual based on first and last enrollment date.

**MTN 011 - A Phase 1 Impact of Coitus on Pharmacokinetics Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing
Data as of July 30, 2015**

Female Retention by Site - Group 1

	Cleveland, OH	Pittsburgh, PA	All Sites
Participants Enrolled	12	14	26
Visit 3a/3b			
Participants Expected*	12	14	26
Participants Retained	12 (100%)	14 (100%)	26 (100%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	0 (0%)	0 (0%)
Visit 4a/4b			
Participants Expected*	12	14	26
Participants Retained	11 (92%)	14 (100%)	25 (96%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	1 (8%)	0 (0%)	1 (4%)
Visit 5a			
Participants Expected*	12	14	26
Participants Retained	11 (92%)	13 (93%)	24 (92%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	1 (8%)	1 (7%)	2 (8%)
Visit 5b			
Participants Expected*	12	14	26
Participants Retained	11 (92%)	13 (93%)	24 (92%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	1 (8%)	1 (7%)	2 (8%)
Visit 6a			
Participants Expected*	12	14	26
Participants Retained	10 (83%)	13 (93%)	23 (88%)
Participants Who Missed the Visit	1 (8%)	1 (7%)	2 (8%)
Participants Who are Lost to Follow-up or Terminated Early	1 (8%)	0 (0%)	1 (4%)

**MTN 011 - A Phase 1 Impact of Coitus on Pharmacokinetics Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing
Data as of July 30, 2015**

Female Retention by Site - Group 1

	Cleveland, OH	Pittsburgh, PA	All Sites
Visit 6b			
Participants Expected*	12	14	26
Participants Retained	10 (83%)	13 (93%)	23 (88%)
Participants Who Missed the Visit	1 (8%)	1 (7%)	2 (8%)
Participants Who are Lost to Follow-up or Terminated Early	1 (8%)	0 (0%)	1 (4%)
Visit 7a/7b (Termination)			
Participants Expected*	12	14	26
Participants Retained	11 (92%)	14 (100%)	25 (96%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	1 (8%)	0 (0%)	1 (4%)

**MTN 011 - A Phase 1 Impact of Coitus on Pharmacokinetics Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing
Data as of July 30, 2015**

Female Retention by Site - Group 2

	Cleveland, OH	Pittsburgh, PA	All Sites
Participants Enrolled	1	4	5
Visit 3a/3b			
Participants Expected*	1	3	4
Participants Retained	1 (100%)	3 (100%)	4 (100%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	0 (0%)	0 (0%)
Visit 4			
Participants Expected*	1	3	4
Participants Retained	0 (0%)	2 (67%)	2 (50%)
Participants Who Missed the Visit	1 (100%)	0 (0%)	1 (25%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	1 (33%)	1 (25%)
Visit 5			
Participants Expected*	1	3	4
Participants Retained	0 (0%)	2 (67%)	2 (50%)
Participants Who Missed the Visit	1 (100%)	0 (0%)	1 (25%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	1 (33%)	1 (25%)
Visit 6			
Participants Expected*	1	3	4
Participants Retained	1 (100%)	2 (67%)	3 (75%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	1 (33%)	1 (25%)
Visit 7a/7b			
Participants Expected*	1	3	4
Participants Retained	1 (100%)	1 (33%)	2 (50%)
Participants Who Missed the Visit	0 (0%)	1 (33%)	1 (25%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	1 (33%)	1 (25%)

**MTN 011 - A Phase 1 Impact of Coitus on Pharmacokinetics Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing
Data as of July 30, 2015**

Female Retention by Site - Group 2

	Cleveland, OH	Pittsburgh, PA	All Sites
Visit 8			
Participants Expected*	1	3	4
Participants Retained	1 (100%)	1 (33%)	2 (50%)
Participants Who Missed the Visit	0 (0%)	1 (33%)	1 (25%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	1 (33%)	1 (25%)
Visit 9 (Termination)			
Participants Expected*	1	3	4
Participants Retained	1 (100%)	2 (67%)	3 (75%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	1 (33%)	1 (25%)

**MTN 011 - A Phase 1 Impact of Coitus on Pharmacokinetics Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing
Data as of July 30, 2015**

Male Retention by Site - Group 1

	Cleveland, OH	Pittsburgh, PA	All Sites
Participants Enrolled	12	14	26
Visit 3a/3b			
Participants Expected*	12	14	26
Participants Retained	12 (100%)	14 (100%)	26 (100%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	0 (0%)	0 (0%)
Visit 5a			
Participants Expected*	12	14	26
Participants Retained	11 (92%)	12 (86%)	23 (88%)
Participants Who Missed the Visit	0 (0%)	1 (7%)	1 (4%)
Participants Who are Lost to Follow-up or Terminated Early	1 (8%)	1 (7%)	2 (8%)
Visit 7a/7b (Termination)			
Participants Expected*	12	14	26
Participants Retained	11 (92%)	13 (93%)	24 (92%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	1 (8%)	1 (7%)	2 (8%)

**MTN 011 - A Phase 1 Impact of Coitus on Pharmacokinetics Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing
Data as of July 30, 2015**

Male Retention by Site - Group 2

	Cleveland, OH	Pittsburgh, PA	All Sites
Participants Enrolled	1	4	5
Visit 3a/3b			
Participants Expected*	1	3	4
Participants Retained	1 (100%)	2 (67%)	3 (75%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	1 (33%)	1 (25%)
Visit 7a/7b			
Participants Expected*	1	3	4
Participants Retained	1 (100%)	1 (33%)	2 (50%)
Participants Who Missed the Visit	0 (0%)	1 (33%)	1 (25%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	1 (33%)	1 (25%)
Visit 9 (Termination)			
Participants Expected*	1	3	4
Participants Retained	0 (0%)	0 (0%)	0 (0%)
Participants Who Missed the Visit	0 (0%)	0 (0%)	0 (0%)
Participants Who are Lost to Follow-up or Terminated Early	0 (0%)	2 (67%)	2 (50%)